Cargando…

Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica

Amebiasis caused by Entamoeba histolytica is the third leading cause of parasitic mortality globally, with some 100,000 deaths annually, primarily among young children. Protective immunity to amebiasis is associated with fecal IgA and IFN-γ in humans; however, no vaccine exists. We have previously i...

Descripción completa

Detalles Bibliográficos
Autores principales: Abhyankar, Mayuresh M., Orr, Mark T., Lin, Susan, Suraju, Mohammed O., Simpson, Adrian, Blust, Molly, Pham, Tiep, Guderian, Jeffrey A., Tomai, Mark A., Elvecrog, James, Pedersen, Karl, Petri, William A., Fox, Christopher B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988657/
https://www.ncbi.nlm.nih.gov/pubmed/29900011
http://dx.doi.org/10.1038/s41541-018-0060-x
_version_ 1783329318945947648
author Abhyankar, Mayuresh M.
Orr, Mark T.
Lin, Susan
Suraju, Mohammed O.
Simpson, Adrian
Blust, Molly
Pham, Tiep
Guderian, Jeffrey A.
Tomai, Mark A.
Elvecrog, James
Pedersen, Karl
Petri, William A.
Fox, Christopher B.
author_facet Abhyankar, Mayuresh M.
Orr, Mark T.
Lin, Susan
Suraju, Mohammed O.
Simpson, Adrian
Blust, Molly
Pham, Tiep
Guderian, Jeffrey A.
Tomai, Mark A.
Elvecrog, James
Pedersen, Karl
Petri, William A.
Fox, Christopher B.
author_sort Abhyankar, Mayuresh M.
collection PubMed
description Amebiasis caused by Entamoeba histolytica is the third leading cause of parasitic mortality globally, with some 100,000 deaths annually, primarily among young children. Protective immunity to amebiasis is associated with fecal IgA and IFN-γ in humans; however, no vaccine exists. We have previously identified recombinant LecA as a potential protective vaccine antigen. Here we describe the development of a stable, manufacturable PEGylated liposomal adjuvant formulation containing two synthetic Toll-like receptor (TLR) ligands: GLA (TLR4) and 3M-052 (TLR7/8). The liposomes stimulated production of monocyte/macrophage chemoattractants MCP-1 and Mip-1β, and Th1-associated cytokines IL-12p70 and IFN-γ from human whole blood dependent on TLR ligand composition and dose. The liposomes also demonstrated acceptable physicochemical compatibility with the recombinant LecA antigen. Whereas mice immunized with LecA and GLA-liposomes demonstrated enhanced antigen-specific fecal IgA titers, mice immunized with LecA and 3M-052-liposomes showed a stronger Th1 immune profile. Liposomes containing GLA and 3M-052 together elicited both LecA-specific fecal IgA and Th1 immune responses. Furthermore, the quality of the immune response could be modulated with modifications to the liposomal formulation based on PEG length. Compared to subcutaneous administration, the optimized liposome adjuvant composition with LecA antigen administered intranasally resulted in significantly enhanced fecal IgA, serum IgG2a, as well as systemic IFN-γ and IL-17A levels in mice. The optimized intranasal regimen provided greater than 80% protection from disease as measured by parasite antigen in the colon. This work demonstrates the physicochemical and immunological characterization of an optimized mucosal adjuvant system containing a combination of TLR ligands with complementary activities and illustrates the importance of adjuvant composition and route of delivery to enhance a multifaceted and protective immune response to amebiasis.
format Online
Article
Text
id pubmed-5988657
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59886572018-06-13 Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica Abhyankar, Mayuresh M. Orr, Mark T. Lin, Susan Suraju, Mohammed O. Simpson, Adrian Blust, Molly Pham, Tiep Guderian, Jeffrey A. Tomai, Mark A. Elvecrog, James Pedersen, Karl Petri, William A. Fox, Christopher B. NPJ Vaccines Article Amebiasis caused by Entamoeba histolytica is the third leading cause of parasitic mortality globally, with some 100,000 deaths annually, primarily among young children. Protective immunity to amebiasis is associated with fecal IgA and IFN-γ in humans; however, no vaccine exists. We have previously identified recombinant LecA as a potential protective vaccine antigen. Here we describe the development of a stable, manufacturable PEGylated liposomal adjuvant formulation containing two synthetic Toll-like receptor (TLR) ligands: GLA (TLR4) and 3M-052 (TLR7/8). The liposomes stimulated production of monocyte/macrophage chemoattractants MCP-1 and Mip-1β, and Th1-associated cytokines IL-12p70 and IFN-γ from human whole blood dependent on TLR ligand composition and dose. The liposomes also demonstrated acceptable physicochemical compatibility with the recombinant LecA antigen. Whereas mice immunized with LecA and GLA-liposomes demonstrated enhanced antigen-specific fecal IgA titers, mice immunized with LecA and 3M-052-liposomes showed a stronger Th1 immune profile. Liposomes containing GLA and 3M-052 together elicited both LecA-specific fecal IgA and Th1 immune responses. Furthermore, the quality of the immune response could be modulated with modifications to the liposomal formulation based on PEG length. Compared to subcutaneous administration, the optimized liposome adjuvant composition with LecA antigen administered intranasally resulted in significantly enhanced fecal IgA, serum IgG2a, as well as systemic IFN-γ and IL-17A levels in mice. The optimized intranasal regimen provided greater than 80% protection from disease as measured by parasite antigen in the colon. This work demonstrates the physicochemical and immunological characterization of an optimized mucosal adjuvant system containing a combination of TLR ligands with complementary activities and illustrates the importance of adjuvant composition and route of delivery to enhance a multifaceted and protective immune response to amebiasis. Nature Publishing Group UK 2018-06-05 /pmc/articles/PMC5988657/ /pubmed/29900011 http://dx.doi.org/10.1038/s41541-018-0060-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Abhyankar, Mayuresh M.
Orr, Mark T.
Lin, Susan
Suraju, Mohammed O.
Simpson, Adrian
Blust, Molly
Pham, Tiep
Guderian, Jeffrey A.
Tomai, Mark A.
Elvecrog, James
Pedersen, Karl
Petri, William A.
Fox, Christopher B.
Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
title Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
title_full Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
title_fullStr Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
title_full_unstemmed Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
title_short Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
title_sort adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for entamoeba histolytica
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988657/
https://www.ncbi.nlm.nih.gov/pubmed/29900011
http://dx.doi.org/10.1038/s41541-018-0060-x
work_keys_str_mv AT abhyankarmayureshm adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT orrmarkt adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT linsusan adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT surajumohammedo adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT simpsonadrian adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT blustmolly adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT phamtiep adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT guderianjeffreya adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT tomaimarka adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT elvecrogjames adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT pedersenkarl adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT petriwilliama adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica
AT foxchristopherb adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica